APA House Call: Treating Trauma Patients During the COVID-19 Pandemic

Article

It might be particularly difficult for psychiatrists to treat trauma patients through telehealth means.

The 2020 American Psychiatric Association (APA) Annual Meeting was cancelled this year, with plans made to convert the world-leading psychiatry conference into a two-part virtual session and educational platform for attendees.

In lieu of regular on-site coverage, HCPLive® will be running a series of interviews, insights, and reporting on topics that frequently headline the APA meeting—featuring familiar experts.

As the coronavirus disease 2019 (COVID-19) pandemic forces virtually the entire world into social isolation, the medical field has taken to telehealth as a reasonable way to maintain non-urgent care without increasing the risk of infection.

Psychiatry might be 1 of the fields leading this charge, as many practices have already implemented some telehealth into their services.

However, some conditions may be more difficult than others to treat under these new circumstances.

In an interview with HCPLive®, David H. Jiang, MD, an assistant professor of psychiatry at Mount Sinai Morningside, explained how trauma might be particularly difficult to treat in the age of social isolation because the sense of trust is a major part of healing for trauma patients and they are often unable to regain that sense of comfort from telehealth appointments.

With that said, Jiang said psychiatrists must find a way to reach their patients and help them through this troubling time

Jiang also discussed how nurses and doctors may be more at risk for developing signs of trauma due to the unsustainable level of strain the COVID-19 virus is putting on the healthcare system and how prevalent feelings of disassociation may be for trauma patients.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
© 2024 MJH Life Sciences

All rights reserved.